Table 3.
Selected secondary endpoints.
| Tacrolimus/Sirolimus N = 318 | Tacrolimus/MMF N = 316 | |
|---|---|---|
| Acute Rejection, Number (%) | 82 (25.8) | 77 (24.4) |
|
| ||
| Biopsy confirmed acute rejection, Number (%): | 48 (15.1)a | 39 (12.3)a |
| Spontaneously resolving | 1 (0.3) | 0 (0.0) |
| Corticosteroid sensitive | 34 (10.7) | 32 (10.1) |
| Corticosteroid resistant | 14 (4.4) | 8 (2.5) |
| Resolved with further treatment | 12 (3.8) | 8 (2.5) |
| Other | 1 (0.3) | 0 (0.0) |
|
| ||
| Histological grade, Number (%): | ||
| Mild (Banff I) | 30 (9.4) | 20 (6.3) |
| Moderate (Banff II) | 17 (5.3) | 17 (5.4) |
| Severe (Banff III) | 1 (0.3) | 2 (0.6) |
|
| ||
| Patient survivalb, % | 99.0 | 99.0 |
|
| ||
| Graft survivalb, % | 92.7 | 93.3 |
FAS
aMore than one BCAR episode was reported for some patients.
bKaplan-Meier estimates.